EPCA-2: a highly specific serum marker for prostate cancer.

Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst (2010) 2.29

Prostate-specific antigen/solvent interaction analysis: a preliminary evaluation of a new assay concept for detecting prostate cancer using urinary samples. Urology (2011) 1.38

Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res (2009) 1.09

Newer potential biomarkers in prostate cancer. Rev Urol (2007) 1.09

Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin Chem (2008) 1.01

Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol (2016) 1.00

Nuclear structure as a source of cancer specific biomarkers. J Cell Biochem (2008) 0.97

Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. Biomed Res Int (2013) 0.93

Clinical utility of prostate carcinoma molecular diagnostic tests. Rev Urol (2008) 0.93

False hopes, unwarranted fears: the trouble with medical news stories. PLoS Med (2008) 0.92

Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol (2009) 0.92

Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples. Biomark Cancer (2010) 0.91

Markers of dispute. Nat Med (2009) 0.91

Retracted Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2. Prostate (2009) 0.87

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol (2009) 0.85

The present and future of prostate cancer urine biomarkers. Int J Mol Sci (2013) 0.85

Formalized prediction of clinically significant prostate cancer: is it possible? Asian J Androl (2012) 0.84

Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA. Rev Urol (2007) 0.84

Markers for detection of prostate cancer. Cancers (Basel) (2010) 0.82

Serum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese population. PLoS One (2011) 0.78

Urinary Volatile Organic Compounds for the Detection of Prostate Cancer. PLoS One (2015) 0.77

Words of wisdom. Re: EPCA-2: a highly specific serum marker for prostate cancer. Eur Urol (2008) 0.75

Re: EPCA-2: a highly specific serum marker for prostate cancer. J Urol (2012) 0.75

New Prognostic Markers: The Pathway from Research to Clinical Practice. Grand rounds Urol (2009) 0.75

[Active surveillance of localized prostate cancer. Significance of prostate core needle biopsies]. Pathologe (2008) 0.75

Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11

Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02

Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68

Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49

Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics (2005) 5.42

Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66

Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem (2002) 4.42

Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24

African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum (2002) 4.15

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology (2007) 4.02

Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem (2005) 3.71

Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32

Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25

An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21

Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14

Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96

Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol (2012) 2.92

Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79

The effect of shock wave rate on the outcome of shock wave lithotripsy: a meta-analysis. J Urol (2007) 2.78

An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77

Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76

HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics (2005) 2.71

Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68

Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol (2011) 2.65

PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63

Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61

Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44

Multiphasic enhancement patterns of small renal masses (≤4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncocytoma. Urology (2013) 2.42

Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38

SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35

Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33

Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology (2010) 2.27

Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23

Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol (2011) 2.20

Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17

Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17

Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem (2005) 2.13

Urinary outcomes are significantly affected by nerve sparing quality during radical prostatectomy. Urology (2013) 2.11

National Institutes of Health state-of-the-science conference statement: prevention of fecal and urinary incontinence in adults. Ann Intern Med (2008) 2.10

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10

Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07

External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology (2008) 2.04

A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations. Clin Chem (2009) 2.01

Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol (2004) 1.95

Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95

Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res (2006) 1.93

Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (2002) 1.90

Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol (2004) 1.85

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.84

Proteomics: a new diagnostic frontier. Clin Chem (2006) 1.82

Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol (2005) 1.81

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80

Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78

Early identification of individuals with prostate cancer in negative biopsies. J Urol (2004) 1.78

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75

Sex prevalence of pediatric kidney stone disease in the United States: an epidemiologic investigation. Urology (2009) 1.74

Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res (2004) 1.74

Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res (2008) 1.74

Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols. BJU Int (2014) 1.73

Validity of administrative coding in identifying patients with upper urinary tract calculi. J Urol (2010) 1.72

Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med (2002) 1.72

Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol (2007) 1.72